stockportfolio.pro
Regeneron Pharmaceuticals, Inc. P/E Ratio 2008–2025
Regeneron Pharmaceuticals, Inc. (REGN) annual price-to-earnings ratio by fiscal year, computed from SEC filings. Compound growth -1.8%/yr over 17 years.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 18.56 | +0.7% |
| FY 2024 | 18.43 | -26.4% |
| FY 2023 | 25.05 | +33.8% |
| FY 2022 | 18.72 | +115.1% |
| FY 2021 | 8.70 | -44.6% |
| FY 2020 | 15.70 | -22.2% |
| FY 2019 | 20.17 | +15.9% |
| FY 2018 | 17.40 | -51.8% |
| FY 2017 | 36.06 | -23.7% |
| FY 2016 | 47.28 | -51.5% |
| FY 2015 | 97.54 | -28.6% |
| FY 2014 | 136.54 | +86.1% |
| FY 2013 | 73.38 | +191.9% |
| FY 2012 | 25.14 | — |
| FY 2011 | — | — |
| FY 2010 | — | — |
| FY 2009 | — | — |
| FY 2008 | — | — |
Source: Regeneron Pharmaceuticals, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Refreshed nightly.
See the full picture for Regeneron Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeRegeneron Pharmaceuticals, Inc. — frequently asked questions
What is Regeneron Pharmaceuticals, Inc.'s price-to-earnings ratio?
Regeneron Pharmaceuticals, Inc. (REGN) reported price-to-earnings ratio of 18.56 for fiscal year 2025, per its SEC filings.
How has Regeneron Pharmaceuticals, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2008 and 2025, REGN's price-to-earnings ratio declined at roughly 1.8% per year (compound annual rate), from 25.14 to 18.56.
Where does this data come from?
Figures are computed from Regeneron Pharmaceuticals, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.